昌吉好的妇科医院人流(昌吉男科医院的电话) (今日更新中)

TAIYUAN, May 29 (Xinhua) -- Parents of children with cerebral palsy are going to have a place to turn for help, as the first public foundation to provide aid has been set up in northern Shanxi Province.The Brain Rehabilitation Fund was established on Saturday by the China Population Welfare Foundation (CPWF), which is headquartered in Beijing. The CPWF will cooperate with the Shanxi Cerebral Palsy Hospital, which specializes in curing the brain disease with therapies such as acupuncture and massage.Lan Ye, the deputy secretary general of the CPWF, said the fund aims to relieve the burden of affected families by providing financial assistance and training so parents are able to do the therapy at home. In addition, the fund hopes to reduce the incidence of cerebral palsy by publicizing preventative measures to thwart the disease.More than 6 million suffer from cerebral palsy in China, and among them more than 2 million are children, said Guo Xinzhi, vice president of the Shanxi's Federation of the Disabled."A family needs to spend more than 500,000 yuan (77,000 U.S. dollars) to cure a child with the disease," Guo said. "As 70 percent of the children with cerebral palsy are from poor, mountainous areas, more than 25.7 percent of families cannot afford to pay the medical expenses."On Saturday, 25 parents from Xinjiang Uygur Autonomous Region, Fujian, Henan and Shanxi provinces came to the hospital for free training on helping their children to recover at home.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

LOS ANGELES, July 27 (Xinhua) -- The Juno spacecraft of the National Aeronautics and Space Administration (NASA) arrived at its launch pad at the Cape Canaveral Air Force Station in Florida on Wednesday, ready for a mission to Jupiter to study the solar system, the Jet Propulsion Laboratory (JPL) said.The solar-powered, Jupiter-bound spacecraft was secured into place on top of its rocket at 10:42 a.m. EDT (7:42 a.m. PDT), said JPL in Pasadena, California.Juno will arrive at Jupiter in July 2016 and orbit its poles 33 times to learn more about the gas giant's interior, atmosphere and aurora, according to JPL."We're about to start our journey to Jupiter to unlock the secrets of the early solar system," said Scott Bolton, the mission 's principal investigator from the Southwest Research Institute in San Antonio, Texas. "After eight years of development, the spacecraft is ready for its important mission."Now that the Juno payload is atop the most powerful Atlas rocket ever made -- the United Launch Alliance Atlas V 551 -- a final flurry of checks and tests can begin and confirm that all is go for launch, according to JPL.The final series of checks begins Wednesday with an on-pad functional test. The test is designed to confirm that the spacecraft is healthy after the fueling, encapsulation and transport operations."The on-pad functional test is the first of seven tests and reviews that Juno and its flight team will undergo during the spacecraft's last 10 days on Earth," said Jan Chodas, Juno's project manager at JPL. "There are a number of remaining pre- launch activities that we still need to focus on, but the team is really excited that the final days of preparation, which we've been anticipating for years, are finally here. We are ready to go. "The launch period for Juno opens Aug. 5, 2011, and extends through Aug. 26. For an Aug. 5 liftoff, the launch window opens at 11:34 a.m. EDT (8:34 a.m. PDT) and remains open through 12:43 p.m. EDT (9:43 a.m. PDT), JPL said.Managed by JPL, the Juno mission is part of the New Frontiers Program managed at NASA's Marshall Space Flight Center in Huntsville, Alaska.

WASHINGTON, July 27 (Xinhua) -- The solar-powered, Jupiter- bound Juno spacecraft was secured into place on top of its rocket Wednesday in preparation for launch next month, the U.S. National Aeronautics and Space Administration (NASA) announced.The launch period for Juno opens Aug. 5 and extends through Aug. 26. For an Aug. 5 liftoff, the launch window opens at 11:34 a.m. EDT (1534 GMT) and remains open through 12:43 EDT (1643 GMT).Juno will arrive at Jupiter in July 2016 and orbit its poles 33 times to learn more about the gas giant's interior, atmosphere and aurora."We're about to start our journey to Jupiter to unlock the secrets of the early solar system," said Scott Bolton, the mission 's principal investigator from the Southwest Research Institute in San Antonio. "After eight years of development, the spacecraft is ready for its important mission."

BEIJING, Sept. 4 (Xinhua) -- China's railway system has transported some 1.27 billion passengers during the first eight months of this year, up 11.8 percent from a year earlier, the Ministry of Railways said Sunday.The figure has accounted for 67.4 percent of the ministry's full-year target, said the ministry in a statement on its website.The Ministry of Railways has planned to send 1.9 billion passengers in 2011, up 13.1 percent year-on-year.The country's high-speed trains had been operating with improved order and efficiency, said the ministry, which has been required to run high-speed trains at slower speeds, as well as to reorganize bullet train schedules nationwide, for safety reasons.The State Council, or Cabinet, ordered increased safety checks after a fatal train collision that killed 40 people in July raised concerns over the safety of the country's high-speed railways.The ministry cut the number of high-speed trains running between Beijing and Shanghai to 66 pairs from 88 pairs per day, effective as of Aug. 16.Meanwhile, the railways transported more than 2.6 billion metric tons of goods from January to August, up 7.8 percent year-on-year, the ministry said.

来源：资阳报